Doktor axborotnomasi 2026, №3 (124)
Subject of the article
БОЛАЛАРДА ЛАНГЕРГАНС ҲУЖАЙРАЛИ ГИСТИОЦИТОЗНИНИГ ТАШҲИС ҚЎЙИШДАГИ КЕЧИКИШ (73-79)
Authors
Х. М. Рустамова, Д. Ф. Маматкулова, И. И. Собиржонов, Д. Ш. Полатова
Institution
Болалар онкологияси, гематологияси ва иммунологияси илмий-амалий тиббиёт маркази (БОГИИАТМ), Тошкент, Ўзбекистон
Abstract
Марказий Осиёда болалар Лангерганс ҳужайрали гистиоцитози (ЛҲГ) бўйича маълумотлар кам. Ушбу миллий ретроспектив тадқиқот (2018–2026) Ўзбекистонда 100 нафар гистологик тасдиқланган ЛҲГ билан касалланган болани (63% ўғил, 37% қиз) қамраб олди. Ташҳис қўйишдаги ёш медианаси — 2,7 ёш; умумий ташҳис интервали медианаси — 82,5 кун (кечикишнинг асосий қисми шифокор даражасида). Миллий аниқла ниш даражаси — 1,6/10⁶ (халқаро 4–9/10⁶ дан паст), ҳудудлар орасида 9 баравар фарқ мавжуд (энг паст — Қашқадарё, Андижон, Самарқанд, Фарғона). Хулоса: Ўзбекистонда ЛҲГ ташҳисида сезиларли кечикиш ва минтақавий тафовут кузатилади; онкохушёрликни ошириш, йўналтириш протоколларини стандартлаштириш ва миллий реестр яратиш зарур.
Key words
Таянч сўзлар: Лангерганс ҳужайрали гистиоцитоз; ташҳис кечикиши; Ўзбекистон. Ключевые слова: лангергансоклеточный гистиоцитоз; задержка диагностики; Узбекистан. Key words: Langerhans cell histiocytosis; diagnostic delay; Uzbekistan.
Literature
1. Рустамова Х., Полатова Д., Мамедова Г. Ўзбекистонда болаларда хавфли ўсмаларни эрта аниқлаш: бир ламчи бўғин тиббиёт тизимида онкологик ҳушёрликни жорий этиш. O‘zbekiston vrachlar assotsiatsiyasi byulleteni 2026 (1), 11-14. 2. Рустамова Х.М., Полатова Дж.Ш., Абдуғаниева Х.Ў., Жахонгирова М.А. Чақалоқда лангерҳанс хужайрали гистиоцитоз: оғиз бўшлиғи ва юқори жағ суягининг зарарланиши, О‘zbekiston tibbiyot jurnali 3 (3), 319-325, 2026. 3. Рустамова Х.М., Собиржонов И.И., Кахарова К.А., Хамроев Х.Ж. Цитокиновый профиль и иммунологиче ские параметры у детей с лангергансоклеточным гистиоцитозом. О‘zbekiston tibbiyot jurnali 3 (3), 306-314, 2026. 4. Atun R, Bhakta N, Denburg A, et al. Sustainable care for children with cancer: a Lancet Oncology Commission. Lancet Oncol. 2020;21(4):e185–e224. 5. Badalian-Very G, Vergilio JA, Degar BA, et al. Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood. 2010;116(11):1919–1923. 6. Cotache-Condor C, Kantety V, Grimm A, et al. Determinants of delayed childhood cancer care in low- and middle-income countries: a systematic review. Pediatr Blood Cancer. 2023;70(4):e30175. 7. Emile JF, Abla O, Fraitag S, et al.; Histiocyte Society. Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Blood. 2016;127(22):2672–2681. 8. Gadner H, Grois N, Pötschger U, et al. Improved outcome in multisystem Langerhans cell histiocytosis is associat ed with therapy intensification. Blood. 2008;111(5):2556–2562. 9. Gadner H, Minkov M, Grois N, et al. Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis. Blood. 2013;121(25):5006–5014. 10. Grois N, Pötschger U, Prosch H, et al. Risk factors for diabetes insipidus in Langerhans cell histiocytosis. Pediatr Blood Cancer. 2006;46(2):228–233. 11. Gupta S, Howard SC, Hunger SP, et al. Treating childhood cancer in low- and middle-income countries. In: Gel band H, Jha P, Sankaranarayanan R, et al., eds. Cancer: Disease Control Priorities. 3rd ed. Vol 3. Washington, DC: World Bank; 2015. 12. Guyot-Goubin A, Donadieu J, Barkaoui M, Bellec S, Thomas C, Clavel J. Descriptive epidemiology of childhood Langerhans cell histiocytosis in France, 2000–2004. Pediatr Blood Cancer. 2008;51(1):71–75. 13. Haupt R, Minkov M, Astigarraga I, et al.; Euro Histio Network. Langerhans cell histiocytosis (LCH): guidelines for diagnosis, clinical work-up, and treatment for patients till the age of 18 years. Pediatr Blood Cancer. 2013;60 (2):175–184. 14. Joko-Fru WY, Parkin DM, Borok M, et al. Survival from childhood cancers in eastern Africa: a population-based registry study. Int J Cancer. 2018;143(10):2409–2415. 15. Rustamova Kh, Polatova D, Rustamov A. Langerhans Cell Histiocytosis (LCH) in Uzbekistan: Analysis of Prog nostic Factors and Outcomes. PEDIATRIC BLOOD & CANCER 72, P790-P791, 2025. 16. Salotti JA, Nanduri V, Pearce MS, Parker L, Lynn R, Windebank KP. Incidence and clinical features of Langer hans cell histiocytosis in the UK and Ireland. Arch Dis Child. 2009;94(5):376–380. 17. von Elm E, Altman DG, Egger M, et al.; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statemen 18. Ward ZJ, Yeh JM, Bhakta N, Frazier AL, Girardi F, Atun R. Global childhood cancer survival estimates and prior ity-setting: a simulation-based analysis. Lancet Oncol. 2019;20(7):972–983. 19. Weller D, Vedsted P, Rubin G, et al. The Aarhus statement: improving design and reporting of studies on early cancer diagnosis. Br J Cancer. 2012;106(7):1262–1267.